Tadalafil Tablets Recalled for Incorrect Product Formulation
Sun Pharmaceutical Industries is recalling Tadalafil 5 mg tablets (Lot # DNC1127A) because an incorrect grade of Crospovidone was used during manufacturing. The product was distributed to one distributor who may have further distributed it nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving a formulation defect (incorrect excipient grade). No illnesses or injuries are reported in the source text, and no specific safety outcome is stated. The recall appears to be precautionary in nature, warranting a Moderate severity rating.
Plain-English summary
Sun Pharmaceutical Industries Inc is recalling Tadalafil Tablets, USP 5 mg, 30-count bottles due to incorrect product formulation. An incorrect grade of Crospovidone was used to manufacture the product. This is a Class II recall issued by the FDA.
The affected product includes Lot # DNC1127A with an expiration date of 05/2023, bearing NDC # 16714-075-01. Approximately 73,957 30-count bottles were affected. The product was distributed to one distributor who may have further distributed the product nationwide.
Consumers who have this product should consult their healthcare provider or pharmacist for guidance. Healthcare providers and pharmacists should quarantine the product and return it to the manufacturer.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # DNC1127A
- exp. date 05/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by SUN PHARMACEUTICAL INDUSTRIES INC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · TADALAFIL
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModerateTadalafil Tablets 20 mg recalled due to manufacturing deviations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same manufacturer · SUN PHARMACEUTICAL INDUSTRIES INC
See all →- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- HighPerampanel Prescription Tablets Recalled for Labeling Mix-up
FDA (Drugs) · 2026-07-01
- HighBudesonide inhalation ampules contain black and brown specks and particles
FDA (Drugs) · 2026-06-17
- SevereDoxorubicin liposome injection vials contain glass particulate matter
FDA (Drugs) · 2026-06-17
Same hazard · formulation defect
See all →- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
- HighSunitinib Malate Capsules Recalled Due to Excess Moisture Content
FDA (Drugs) · 2023-07-19
- HighPrescription Drug Recall: Extended Phenytoin Sodium Dissolution Failure
FDA (Drugs) · 2023-06-21
- HighDialysate Concentrate for Hemodialysis Recalled for Out-of-Specification Formulation
FDA (Devices) · 2021-06-23